Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.

International journal of oncology - 1 Dec 2022

Guo Huihui, Zhang Xilin, Xie Shangzhi, Chen Tianwei, Xie Dong, Cai Ying, Cui Dawei, Wang Liang, Chen Wei, Wang Xiang

Abstract excerpt

Gefitinib is a sensitive and effective drug to treat non‑small‑cell lung cancer (NSCLC) carrying the somatic activating mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR). In the present study, a new mechanism of action of gefitinib in EGFR‑mutated NSCLC cells was discovered using in vitro co‑culture of NSCLC cells with peripheral blood mononuclear cells (PBMCs). Gefitinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Leukocytes, Mononuclear

Share to Lung Neoplasms

Share to Mutation

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 36205136
DOI: 10.3892/ijo.2022.5436
PMCID: PMC9581114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.PMID 36205136Read ↗

Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.Semantic proximity Read ↗

EPHA5 mutation impairs natural killer cell-mediated cytotoxicity against non-small lung cancer cells and promotes cancer cell migration and invasion.Semantic proximity Read ↗

B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor Mutation Patterns.Semantic proximity Read ↗

B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor ImmunitySemantic proximity Read ↗

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancerSemantic proximity Read ↗

The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and SurvivalSemantic proximity Read ↗

EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer.Semantic proximity Read ↗

B7-H5 costimulates human T cells via CD28HSemantic proximity Read ↗

A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer.Semantic proximity Read ↗

Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.Semantic proximity Read ↗

Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.